Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$8.23 USD

8.23
1,106,208

+0.60 (7.86%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kinjel Shah headshot

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Company News for Mar 12, 2020

Companies In The News Are: TLSA, VIR, HEAR, CDMO

Vir (VIR) Looks Good: Stock Adds 12.9% in Session

Vir (VIR) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals

The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Manaswita Ghosh Dutta headshot

House Okays $8 Billion Funds to Combat COVID-19: 3 Winners

U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.

Daniel Laboe headshot

Coronavirus Stocks

Keep your eyes peeled for updates on this new strain of the Coronavirus as it may have a wide-spread impact on the markets.

Indrajit Bandyopadhyay headshot

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.